In the latest session, Celldex Therapeutics Inc. (NASDAQ: CLDX) closed at $39.19 down -3.52% from its previous closing price of $40.62. In other words, the price has decreased by -$1.43 from its previous closing price. On the day, 785229 shares were traded.
Ratios:
For a deeper understanding of Celldex Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.87 and its Current Ratio is at 13.87. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 10, 2023, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $27.
On August 22, 2023, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $21.Wells Fargo initiated its Underweight rating on August 22, 2023, with a $21 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2.67B and an Enterprise Value of 2.25B. For the stock, the TTM Price-to-Sale (P/S) ratio is 366.95 while its Price-to-Book (P/B) ratio in mrq is 5.10. Its current Enterprise Value per Revenue stands at 326.55 whereas that against EBITDA is -16.17.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is 41.49, while the 200-Day Moving Average is calculated to be 34.12.
Shares Statistics:
For the past three months, CLDX has traded an average of 973.81K shares per day and 623.31k over the past ten days. A total of 64.42M shares are outstanding, with a floating share count of 62.84M. Insiders hold about 2.83% of the company’s shares, while institutions hold 94.17% stake in the company. Shares short for CLDX as of Mar 28, 2024 were 6.56M with a Short Ratio of 6.73, compared to 6.41M on Feb 29, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.98% and a Short% of Float of 11.44%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.69 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$0.75, while EPS last year was -$0.62. The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.67 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$2.75 and -$3.55 for the fiscal current year, implying an average EPS of -$3.01. EPS for the following year is -$3.09, with 6 analysts recommending between -$1.76 and -$3.93.
